The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer

Kyoko Yamaguchi, Hitoshi Kusaba, Akitaka Makiyama, Kenji Mitsugi, Keita Uchino, Shingo Tamura, Yoshihiro Shibata, Taito Esaki, Mamoru Ito, Kotoe Takayoshi, Kenji Tsuchihashi, Shuji Arita, hiroshi ariyama, Koichi Akashi, Eishi Baba

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Purpose: Peripheral sensory neuropathy (PSN) and thrombocytopenia are the main dose-limiting toxicities of oxaliplatin for the treatment of advanced gastric cancer (AGC). Because the risk factors for those toxicities in practice have not been clarified, we conducted this prospective study. Methods: AGC patients who received oxaliplatin-based therapy at any of seven institutions participating in the Kyushu Medical Oncology Group were assessed after we obtained written informed consent. Results: A total of 60 patients including 39 males and 21 females were examined. The median age was 66 years. The numbers of patients receiving oxaliplatin as the first, second, or third and later lines of therapy were 39, 16, and 5, respectively. An initial dose of 130, 100, or < 100 mg/m 2 oxaliplatin was administered to 12, 39, and 9 patients, respectively. S-1 or capecitabine as a concomitant drug was administered in 54 and 6 patients, respectively. In multivariate analysis, the comorbidity of diabetes mellitus was associated with ≥ grade 2 thrombocytopenia (p = 0.035). No significant risk factor was associated with ≥ grade 2 PSN. However, the accumulated dose of oxaliplatin exhibited a strong correlation with ≥ grade 2 PSN (p = 0.0043), and the predicted accumulated dose of oxaliplatin in which 10% of patients developed ≥ grade 2 PSN was 800 mg/m 2 . The frequency of PSN in subsequent paclitaxel therapy in patients with ≥ grade 2 or worse PSN in oxaliplatin-based chemotherapy did not increase compared to those with none or grade 1 PSN in oxaliplatin. Conclusion: Thrombocytopenia in AGC patients with diabetes mellitus should be carefully monitored during oxaliplatin-based therapy.

元の言語英語
ページ(範囲)625-633
ページ数9
ジャーナルCancer chemotherapy and pharmacology
82
発行部数4
DOI
出版物ステータス出版済み - 10 1 2018

Fingerprint

oxaliplatin
Peripheral Nervous System Diseases
Thrombocytopenia
Stomach Neoplasms
Medical problems
Toxicity
Diabetes Mellitus
Therapeutics
Oncology
Chemotherapy
Medical Oncology

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

これを引用

The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer. / Yamaguchi, Kyoko; Kusaba, Hitoshi; Makiyama, Akitaka; Mitsugi, Kenji; Uchino, Keita; Tamura, Shingo; Shibata, Yoshihiro; Esaki, Taito; Ito, Mamoru; Takayoshi, Kotoe; Tsuchihashi, Kenji; Arita, Shuji; ariyama, hiroshi; Akashi, Koichi; Baba, Eishi.

:: Cancer chemotherapy and pharmacology, 巻 82, 番号 4, 01.10.2018, p. 625-633.

研究成果: ジャーナルへの寄稿記事

Yamaguchi, Kyoko ; Kusaba, Hitoshi ; Makiyama, Akitaka ; Mitsugi, Kenji ; Uchino, Keita ; Tamura, Shingo ; Shibata, Yoshihiro ; Esaki, Taito ; Ito, Mamoru ; Takayoshi, Kotoe ; Tsuchihashi, Kenji ; Arita, Shuji ; ariyama, hiroshi ; Akashi, Koichi ; Baba, Eishi. / The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer. :: Cancer chemotherapy and pharmacology. 2018 ; 巻 82, 番号 4. pp. 625-633.
@article{e07443fca44c49d1a60c4bd2e8191ff0,
title = "The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer",
abstract = "Purpose: Peripheral sensory neuropathy (PSN) and thrombocytopenia are the main dose-limiting toxicities of oxaliplatin for the treatment of advanced gastric cancer (AGC). Because the risk factors for those toxicities in practice have not been clarified, we conducted this prospective study. Methods: AGC patients who received oxaliplatin-based therapy at any of seven institutions participating in the Kyushu Medical Oncology Group were assessed after we obtained written informed consent. Results: A total of 60 patients including 39 males and 21 females were examined. The median age was 66 years. The numbers of patients receiving oxaliplatin as the first, second, or third and later lines of therapy were 39, 16, and 5, respectively. An initial dose of 130, 100, or < 100 mg/m 2 oxaliplatin was administered to 12, 39, and 9 patients, respectively. S-1 or capecitabine as a concomitant drug was administered in 54 and 6 patients, respectively. In multivariate analysis, the comorbidity of diabetes mellitus was associated with ≥ grade 2 thrombocytopenia (p = 0.035). No significant risk factor was associated with ≥ grade 2 PSN. However, the accumulated dose of oxaliplatin exhibited a strong correlation with ≥ grade 2 PSN (p = 0.0043), and the predicted accumulated dose of oxaliplatin in which 10{\%} of patients developed ≥ grade 2 PSN was 800 mg/m 2 . The frequency of PSN in subsequent paclitaxel therapy in patients with ≥ grade 2 or worse PSN in oxaliplatin-based chemotherapy did not increase compared to those with none or grade 1 PSN in oxaliplatin. Conclusion: Thrombocytopenia in AGC patients with diabetes mellitus should be carefully monitored during oxaliplatin-based therapy.",
author = "Kyoko Yamaguchi and Hitoshi Kusaba and Akitaka Makiyama and Kenji Mitsugi and Keita Uchino and Shingo Tamura and Yoshihiro Shibata and Taito Esaki and Mamoru Ito and Kotoe Takayoshi and Kenji Tsuchihashi and Shuji Arita and hiroshi ariyama and Koichi Akashi and Eishi Baba",
year = "2018",
month = "10",
day = "1",
doi = "10.1007/s00280-018-3652-2",
language = "English",
volume = "82",
pages = "625--633",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer

AU - Yamaguchi, Kyoko

AU - Kusaba, Hitoshi

AU - Makiyama, Akitaka

AU - Mitsugi, Kenji

AU - Uchino, Keita

AU - Tamura, Shingo

AU - Shibata, Yoshihiro

AU - Esaki, Taito

AU - Ito, Mamoru

AU - Takayoshi, Kotoe

AU - Tsuchihashi, Kenji

AU - Arita, Shuji

AU - ariyama, hiroshi

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Purpose: Peripheral sensory neuropathy (PSN) and thrombocytopenia are the main dose-limiting toxicities of oxaliplatin for the treatment of advanced gastric cancer (AGC). Because the risk factors for those toxicities in practice have not been clarified, we conducted this prospective study. Methods: AGC patients who received oxaliplatin-based therapy at any of seven institutions participating in the Kyushu Medical Oncology Group were assessed after we obtained written informed consent. Results: A total of 60 patients including 39 males and 21 females were examined. The median age was 66 years. The numbers of patients receiving oxaliplatin as the first, second, or third and later lines of therapy were 39, 16, and 5, respectively. An initial dose of 130, 100, or < 100 mg/m 2 oxaliplatin was administered to 12, 39, and 9 patients, respectively. S-1 or capecitabine as a concomitant drug was administered in 54 and 6 patients, respectively. In multivariate analysis, the comorbidity of diabetes mellitus was associated with ≥ grade 2 thrombocytopenia (p = 0.035). No significant risk factor was associated with ≥ grade 2 PSN. However, the accumulated dose of oxaliplatin exhibited a strong correlation with ≥ grade 2 PSN (p = 0.0043), and the predicted accumulated dose of oxaliplatin in which 10% of patients developed ≥ grade 2 PSN was 800 mg/m 2 . The frequency of PSN in subsequent paclitaxel therapy in patients with ≥ grade 2 or worse PSN in oxaliplatin-based chemotherapy did not increase compared to those with none or grade 1 PSN in oxaliplatin. Conclusion: Thrombocytopenia in AGC patients with diabetes mellitus should be carefully monitored during oxaliplatin-based therapy.

AB - Purpose: Peripheral sensory neuropathy (PSN) and thrombocytopenia are the main dose-limiting toxicities of oxaliplatin for the treatment of advanced gastric cancer (AGC). Because the risk factors for those toxicities in practice have not been clarified, we conducted this prospective study. Methods: AGC patients who received oxaliplatin-based therapy at any of seven institutions participating in the Kyushu Medical Oncology Group were assessed after we obtained written informed consent. Results: A total of 60 patients including 39 males and 21 females were examined. The median age was 66 years. The numbers of patients receiving oxaliplatin as the first, second, or third and later lines of therapy were 39, 16, and 5, respectively. An initial dose of 130, 100, or < 100 mg/m 2 oxaliplatin was administered to 12, 39, and 9 patients, respectively. S-1 or capecitabine as a concomitant drug was administered in 54 and 6 patients, respectively. In multivariate analysis, the comorbidity of diabetes mellitus was associated with ≥ grade 2 thrombocytopenia (p = 0.035). No significant risk factor was associated with ≥ grade 2 PSN. However, the accumulated dose of oxaliplatin exhibited a strong correlation with ≥ grade 2 PSN (p = 0.0043), and the predicted accumulated dose of oxaliplatin in which 10% of patients developed ≥ grade 2 PSN was 800 mg/m 2 . The frequency of PSN in subsequent paclitaxel therapy in patients with ≥ grade 2 or worse PSN in oxaliplatin-based chemotherapy did not increase compared to those with none or grade 1 PSN in oxaliplatin. Conclusion: Thrombocytopenia in AGC patients with diabetes mellitus should be carefully monitored during oxaliplatin-based therapy.

UR - http://www.scopus.com/inward/record.url?scp=85050604113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050604113&partnerID=8YFLogxK

U2 - 10.1007/s00280-018-3652-2

DO - 10.1007/s00280-018-3652-2

M3 - Article

VL - 82

SP - 625

EP - 633

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -